Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul 2;12(7):1721-7.
doi: 10.1080/21645515.2015.1115164.

A systematic review of the efficacy of live attenuated influenza vaccine upon revaccination of children

Affiliations

A systematic review of the efficacy of live attenuated influenza vaccine upon revaccination of children

Herve Caspard et al. Hum Vaccin Immunother. .

Abstract

Four randomized, double-blind, placebo-controlled studies in 6090 children that investigated the efficacy of live attenuated influenza vaccine (LAIV) upon revaccination of children against laboratory-confirmed cases of influenza in consecutive seasons were reviewed. The efficacy in season 2 of LAIV administered over 2 consecutive seasons was 86.7% (95 % CI: 76.8%, 92.4%) against strains antigenically similar to those contained in the vaccine. The additional efficacy of LAIV administered in season 2 compared to LAIV recipients in season 1 only was 58.4% (28.3%, 75.9%). LAIV administered over 2 consecutive seasons also was more efficacious than was LAIV administered in season 2 only (relative efficacy: 53.9% [17.4%, 74.3%]). Residual efficacy of LAIV administered in season 1 only compared to placebo administered in two consecutive seasons was 56.4% (37.0%, 69.8%). This review did not find any evidence of decreasing efficacy of LAIV when administered during 2 consecutive seasons.

Keywords: children; efficacy; live attenuated influenza vaccine; repeat vaccination; revaccination.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Efficacy in Season 2 of LAIV Administered Over 2 Consecutive Seasons. (A) Against Influenza Strains Antigenically Similar to Those Contained in the Vaccine. (B) Against All Influenza Strains; LAIV=live attenuated influenza vaccine.
Figure 2.
Figure 2.
Article Selection Flowchart. LAIV=live attenuated influenza vaccine.

Similar articles

Cited by

References

    1. Heikkinen T, Heinonen S. Effectiveness and safety of influenza vaccination in children: European perspective. Vaccine 2011; 29:7529–34. PMID:21820481 - PubMed
    1. Ohmit SE, Petrie JG, Malosh RE, Cowling BJ, Thompson MG, Shay DK, Monto AS. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis 2013; 56:1363–9. PMID:3413420 - PMC - PubMed
    1. Ohmit SE, Thompson MG, Petrie JG, Thaker SN, Jackson ML, Belongia EA, Zimmerman RK, Gaglani M, Lamerato L, Spencer SM, et al.. Influenza vaccine effectiveness in the 2011–2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis 2014; 58:319–27. PMID:24235265; http://dx.doi.org/10.1093/cid/cit736 - DOI - PMC - PubMed
    1. Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter AL, Gubbay JB, Dickinson JA, Fonseca K, Charest H, Bastien N, et al.. Influenza A/Subtype and B/Lineage effectiveness estimates for the 2011–2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis 2014; 210:126–37. - PubMed
    1. Bracco Neto H, Farhat CK, Tregnaghi MW, Madhi SA, Razmpour A, Palladino G, Small MG, Gruber WC, Forrest BD. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J 2009; 28:365–71. PMID:19395948 - PubMed

Publication types

LinkOut - more resources